What is Applied Biologics?
Applied Biologics operates as a fully-integrated life sciences enterprise, focusing on the intersection of research, product development, and the distribution of advanced medical technologies. The company is primarily recognized for its expertise in regenerative medicine, with its flagship product, XWRAP, serving as a critical dehydrated amniotic membrane allograft. This technology is engineered to function as a protective barrier for both acute and chronic wound management, addressing significant clinical needs in modern healthcare.
By maintaining rigorous clinical investigation standards and high-quality manufacturing protocols, the company has established itself as a reliable partner for wound care centers and healthcare providers nationwide. Their business model emphasizes not only the delivery of innovative biologic solutions but also the provision of comprehensive clinical support, which is essential for achieving optimal patient outcomes in complex wound care environments.
How much funding has Applied Biologics raised?
Applied Biologics has raised a total of $391K across 2 funding rounds:
Debt
$150K
Debt
$241K
Debt (2020): $150K with participation from PPP
Debt (2021): $241K led by PPP
Key Investors in Applied Biologics
PPP
Public-Private Partnership
What's next for Applied Biologics?
With the successful acquisition of $241K, Applied Biologics is well-positioned to accelerate its commercial expansion and deepen its penetration into the regenerative medicine market. The company's strategic roadmap likely involves scaling the distribution of XWRAP and potentially diversifying its product pipeline to address broader therapeutic applications. As the firm transitions through this late-stage growth phase, the focus will remain on operational efficiency and the expansion of its clinical footprint.
Future growth will be driven by the continued integration of its manufacturing capabilities and the strengthening of partnerships with healthcare providers. By maintaining a commitment to evidence-based medicine and technological innovation, Applied Biologics is poised to sustain its competitive advantage, potentially exploring new market segments or enhancing its existing portfolio to meet the evolving demands of the global wound care industry.
